Results 151 to 160 of about 17,260 (285)

Pseudo-Wellens Syndrome Caused by Myocardial Bridging. [PDF]

JACC Case Rep
Zhou X, Zhao C.
europepmc   +1 more source

A Phase 2 Trial of Frexalimab, a CD40L Antagonist, in Adolescents and Adults With Recent‐Onset Type 1 Diabetes (FABULINUS): Rationale and Study Design

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Introduction Type 1 diabetes (T1D) is a chronic autoimmune disease, characterised by progressive destruction of the insulin‐producing pancreatic β‐cells. Preserving remaining β‐cells at the time of diagnosis may improve long‐term outcomes. Frexalimab is a humanised monoclonal antibody specific for CD40L undergoing evaluation for treatment of ...
Andriy Cherkas, Baerbel Rotthaeuser, Niels Porksen, Pascale Labard, My‐Liên Nguyên‐Pascal, Mathieu Coudert, Baptiste Berthou, Marie Baccara‐Dinet, Gabor Boka, Mark Peakman, Felix Reschke, Michael J. Haller   +11 more
wiley   +1 more source

Functional myocardial bridging resulting in sub-endocardial anterior myocardial infarction

Hellenic Journal of Cardiology, 2023
Linda Kimani, Ragheb Traify, Adeel Shahzad, Matthias Schmitt, Ioannis Dimarakis   +4 more
doaj   +1 more source

Myocardial Bridging and Cardiac Arrest. [PDF]

JACC Case Rep
Iyer KV, Hieger RJ, Rajput R, Raymer KL, Ganesan AP, Khoukaz S, Roukoz B, Mikhail B, Kim JP, Oke VV.   +9 more
europepmc   +1 more source

Evaluation of the Safety, Efficacy and Pharmacokinetics of BGM0504 in Chinese Adults With Type 2 Diabetes: A Multicentre, Randomised, Controlled and Double‐Blind Phase II Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim This study aimed to evaluate its safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy in Chinese adults with T2DM and to preliminarily compare its efficacy and safety with semaglutide through multiple subcutaneous injections. Materials and Methods In this multicentre, randomised, placebo‐controlled and semaglutide‐positive‐
Ping Jin, Linong Ji, Yangqing Huang, Haifeng Ding, Daosheng Xie, Xiaohui Jiang, Xuemei Yuan, Zhao Cao, Haibin Zhang, Jiandong Yuan   +9 more
wiley   +1 more source

Intracoronary Electrocardiography During Dobutamine Stress for Functional Assessment of Myocardial Bridging. [PDF]

JACC Case Rep
Miyazaki Y, Kimpara A, Soh M, Sekine O, Aoyama M, Sumida N, Nishimura T, Inagawa K, Sakamoto M, Toya T.   +9 more
europepmc   +1 more source

Thrombosis and Circulation: From Bench to Bedside

Thrombosis and Circulation Research, EarlyView.
Zhenguo Zhai
wiley   +1 more source

Proteomic Profiling Captures Residual Cardiovascular Risk Beyond the PREVENT Model in Individuals With Cardiovascular–Kidney–Metabolic Syndrome Stages 2–3

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Cardiovascular–kidney–metabolic (CKM) syndrome reflects complex pathobiological interactions among metabolic disorders, kidney injury, and cardiovascular disease (CVD). Stages 2 and 3 represent critical phases of disease progression characterised by high pathological heterogeneity.
Xuefei Han, Jiacheng Ding, Jingqian Li, Yiyin Gao, Yunqian Li   +4 more
wiley   +1 more source

Real-world presentation of myocardial bridging in the cath-lab: a case series. [PDF]

Eur Heart J Case Rep
D'Amario D, Vergallo R, Elia S, Rizzo G, Ricchiuto A, Ciliberti G, Porto I, Patti G.   +7 more
europepmc   +1 more source

Real‐World Use of Emicizumab in Patients With Acquired Haemophilia A: An Interim Safety Analysis of a Large‐Scale Post‑Marketing Surveillance Study

Haemophilia, EarlyView.
ABSTRACT Introduction Acquired haemophilia A (AHA) is a rare autoimmune disorder where the development of autoantibodies to factor (F)VIII neutralise its function, leading to bleeding. Emicizumab has been approved for treating AHA in Japan. Aim This post‐marketing study was performed to primarily examine the use and safety of emicizumab, and indirectly
Midori Shima, Katsuyuki Fukutake, Yoshiyuki Ogawa, Yuta Kamei, Chiaki Sugita, Akinori Yuri, Ryota Kobayashi, Akiko Ioka, Tadashi Matsushita   +8 more
wiley   +1 more source